Clinical Trial: A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

U.S., June 17 -- ClinicalTrials.gov registry received information related to the study (NCT07650916) titled 'A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed' on June 10.

Brief Summary: This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).

Study Start Date: June 29

Study Type: INTERVENTIONAL

Condition: HIV Infections

Intervention: DRUG: CAB ULA

CAB ULA will be administered.

DRUG: RPV ULA

RPV ULA will be administered....